When developing vaccines against COVID-19, 'fast is slow, and slow is fast'
(American Association for the Advancement of Science) Bypassing clinical trials for a potential SARS-CoV-2 vaccine would be " catastrophic, " says Science Advances deputy editor Douglas Green in this Editorial. Instead, it's vital to take time to ensure any vaccine candidate's safety and investigate potential adverse
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
More News: Clinical Trials | COVID-19 | International Medicine & Public Health | SARS | Science | Vaccines